Are you Dr. Ishida?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 33 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
University Of California San Francisco
521 Parnassus Avenue, C443, Box 0532
San Francisco, CA 94143Phone+1 415-476-1812
Summary
- Dr. Julie Ishida, MD is a nephrologist in San Francisco, California. She is currently licensed to practice medicine in California. She is affiliated with UCSF Medical Center and San Francisco VA Medical Center.
Education & Training
- University of California (San Francisco)Fellowship, Nephrology, 2010 - 2012
- University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
- Stanford University School of MedicineClass of 2007
Certifications & Licensure
- CA State Medical License 2009 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Publications & Presentations
PubMed
- 15 citationsMarijuana Use and Estimated Glomerular Filtration Rate in Young AdultsJulie H. Ishida, Reto Auer, Eric Vittinghoff, Mark J. Pletcher, Jared P. Reis
Clinical Journal of the American Society of Nephrology. 2017-10-06 - 32 citationsSources of Information and Beliefs About the Health Effects of MarijuanaJulie H. Ishida, Alysandra J. Zhang, Stacey Steigerwald, Beth E. Cohen, Marzieh Vali
Journal of General Internal Medicine. 2020-01-01 - 10 citationsMuscle Relaxant Use Among Hemodialysis Patients: Prevalence, Clinical Indications, and Adverse OutcomesDiana Mina, Kirsten L. Johansen, Charles E. McCulloch, Michael A. Steinman, Barbara Grimes
American Journal of Kidney Diseases. 2019-04-01
Press Mentions
- Opioids Risky for Hemodialysis PatientsMay 2nd, 2018
- Opioids May Carry Unique Risks for Patients on HemodialysisApril 20th, 2018
- Opioids Risky for Hemodialysis PatientsApril 20th, 2018
- Join now to see all